HCLTs results barely lived up to the Street?s expectations. Nevertheless, we are confident about the company?s IMS and engineering services, and expect growth to pick up. A healthy deal pipeline of US$ 2bn TCV in 3Q bolsters our faith in HCLT. Most of the deals include IMS in various stages of transition. We expect FY17 to be a stronger year led by IMS.